دورية أكاديمية
Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer.
| العنوان: | Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer. |
|---|---|
| المؤلفون: | Nokin MJ; University of Bordeaux, INSERM U1218, ACTION Laboratory, IECB, 33600 Pessac, France., Ambrogio C; Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Nadal E; Department of Medical Oncology, Catalan Institute of Oncology, Clinical Research in Solid Tumors (CReST) Group, Oncobell Program, IDIBELL, L'Hospitalet, Barcelona, Spain. Electronic address: esnadal@iconcologia.net., Santamaria D; University of Bordeaux, INSERM U1218, ACTION Laboratory, IECB, 33600 Pessac, France. Electronic address: d.santamaria@iecb.u-bordeaux.fr. |
| المصدر: | Trends in cancer [Trends Cancer] 2021 May; Vol. 7 (5), pp. 410-429. Date of Electronic Publication: 2020 Dec 09. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Cell Press Country of Publication: United States NLM ID: 101665956 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2405-8025 (Electronic) Linking ISSN: 24058025 NLM ISO Abbreviation: Trends Cancer Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Cambridge, MA] : Cell Press, [2015]- |
| مواضيع طبية MeSH: | Antineoplastic Combined Chemotherapy Protocols/*pharmacology , Carcinoma, Non-Small-Cell Lung/*drug therapy , Lung Neoplasms/*drug therapy , Precision Medicine/*methods , Proto-Oncogene Proteins/*antagonists & inhibitors, Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Carcinogenesis/drug effects ; Carcinogenesis/genetics ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/immunology ; Carcinoma, Non-Small-Cell Lung/mortality ; Clinical Trials as Topic ; Drug Resistance, Neoplasm/drug effects ; Drug Resistance, Neoplasm/genetics ; Drug Synergism ; Humans ; Immune Checkpoint Inhibitors/pharmacology ; Immune Checkpoint Inhibitors/therapeutic use ; Lung Neoplasms/genetics ; Lung Neoplasms/immunology ; Lung Neoplasms/mortality ; Molecular Targeted Therapy/methods ; Mutation ; Progression-Free Survival ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Proto-Oncogene Proteins/genetics |
| مستخلص: | The discovery of oncogenic driver mutations led to the development of targeted therapies with non-small cell lung cancer (NSCLC) being a paradigm for precision medicine in this setting. Nowadays, the number of clinical trials focusing on targeted therapies for uncommon drivers is growing exponentially, emphasizing the medical need for these patients. Unfortunately, similar to what is observed with most targeted therapies directed against a driver oncogene, the clinical response is almost always temporary and acquired resistance to these drugs invariably emerges. Here, we review the biology of infrequent genomic actionable alterations in NSCLC as well as the current and emerging therapeutic options for these patients. Mechanisms leading to acquired drug resistance and future challenges in the field are also discussed. (Copyright © 2020 Elsevier Inc. All rights reserved.) |
| فهرسة مساهمة: | Keywords: NSCLC; drug resistance; infrequent drivers; targeted therapy |
| المشرفين على المادة: | 0 (Immune Checkpoint Inhibitors) 0 (Protein Kinase Inhibitors) 0 (Proto-Oncogene Proteins) |
| تواريخ الأحداث: | Date Created: 20201214 Date Completed: 20211220 Latest Revision: 20211220 |
| رمز التحديث: | 20221213 |
| DOI: | 10.1016/j.trecan.2020.11.005 |
| PMID: | 33309239 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2405-8025 |
|---|---|
| DOI: | 10.1016/j.trecan.2020.11.005 |